SAN FRANCISCO, Aug. 29, 2016 /PRNewswire/ -- Symic, a clinical stage biotherapeutics company developing therapies inspired by naturally occurring molecules of the extracellular matrix, today announced that Ken Horne, Chief Executive Officer, will present at the BioCentury NewsMakers in the Biotech Industry Conference.
Date: Friday, Sept. 9, 2016
Time: 11:30 a.m. EDT
Location: Millennium Broadway Hotel, New York
Symic Bio is a clinical stage biotherapeutics company developing therapies inspired by proteoglycans, naturally occurring macromolecules of the extracellular matrix (ECM). The structural and regulatory properties of proteoglycans have potential applications in a wide variety of disease states. Symic Bio currently has two clinical candidates, one to address complications of vascular injury and one for disease modification in the treatment of osteoarthritis. In addition, Symic Bio is investigating applications in the areas of fibrosis and oncology.
For additional information please visit the company's website at www.symic.bio, LinkedIn page at www.linkedin.com/company/symic-bio/ or follow on Twitter at www.twitter.com/symicbio.
David Schull or Rich Allan
Russo Partners, LLC
For more information:
Last updated on: 29/08/2016
PharmiWeb.com is Europe's leading industry-sponsored portal for the Pharmaceutical sector, providing the latest jobs, news, features and events listings.
The information provided on PharmiWeb.com is designed to support, not replace, the relationship that exists between a patient/site visitor and his/her physician.